Chifeng Bio: Adjuvant quadrivalent influenza vaccine enters Phase I/II clinical trials.

Chia Tai Biological Announcement: The quadrivalent adjuvanted influenza vaccine developed by Chia Tai Longma, a wholly-owned subsidiary of the company, has initiated Phase I/II clinical trials in Hebei Province. The vaccine contains the ZFA02 adjuvant independently developed by the company, which is used to prevent influenza caused by vaccine-related strains. There is currently no adjuvanted influenza vaccine approved for marketing in China, while Seqirus, a foreign company, has had adjuvanted influenza vaccines approved for marketing and use. If the project progresses smoothly, it will further enrich the variety of viral vaccines of the company, improve product layout, and strengthen market competitiveness.